Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC proposes fraud survey

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission requests comments on a proposed consumer fraud survey, which in a 2005 version revealed weight-loss products were the most frequently reported fraud in the U.S. FTC, which lists fraudulent weight-loss products as a key enforcement area, proposes a national telephone survey of up to 4,100 consumers to gather information about consumer fraud (1"The Tan Sheet" Oct. 12, 2009). According to an Aug. 31 Federal Register 2notice, the agency will use the results from its third consumer fraud survey to determine if the type or frequency of fraud is changing. Comments on the proposed survey are due Nov. 1

You may also be interested in...



FTC Intensifies Health Claims Scrutiny, Enforcement Strategies

A joint Federal Trade Commission/FDA working group will evaluate claims made for dietary supplements, conventional foods and OTC drugs, said the commission's Consumer Protection Director David Vladeck

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104470

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel